BC Week In Review | Feb 11, 2008
Company News

DNAPrint, Nanobac deal

The companies signed a letter of intent for Nanobac to acquire pharmacogenetics and consumer genetic test services company DNAPrint for 75 million shares valued at $3 million based on Nanobac's close of $0.04 on Jan....
BioCentury | Dec 10, 2007
Strategy

deCode gets personal

deCode genetics Inc. thinks its new deCODEme personal genotyping service will let it earn a bit of easy cash with very little effort. The company is planning to leverage its understanding of genomics into a...
BC Week In Review | Dec 18, 2006
Clinical News

DNAPrint preclinical data

In a mouse model of anemia, PT-401 was 3 times more effective than conventional erythropoietin (EPO) treatments. PT-401 is dimerized and genetically modified form of EPO. Data were presented at the American Society of Hematology...
BC Week In Review | Aug 28, 2006
Company News

DNAPrint, NeoCodex Inc. deal

DNAG will use its Admixture Mapping technology to identify markers in DNA samples provided by NeoCodex that predict drug response to chemotherapy regimens. DNAPrint Genomics Inc. (DNAG), Sarasota, Fla.   NeoCodex Inc. , Sevilla, Spain  ...
BC Week In Review | Jul 18, 2005
Company News

Biofrontera Pharmaceuticals Holding AG, DNAPrint deal

DNAG acquired an 18% stake in Biofrontera for E1.5 million ($1.8 million). Under the companies' 2004 deal, DNAG can acquire up to 51.4% of Biofrontera (see BioCentury, Oct. 4, 2004). The companies have a JV...
BC Week In Review | Jun 20, 2005
Company News

DNAPrint, Proteos Inc. deal

Proteos, a CRO, will manufacture preclinical batches of DNAP's PT-401 erythropoietin (EPO) dimer to treat anemia. In April, DNAP acquired an exclusive worldwide license to the compound from Beth Israel Deaconess Medical Center (Boston, Mass.)...
BC Week In Review | Apr 11, 2005
Company News

DNAPrint, Beth Israel Deaconess Medical Center deal

DNAP acquired an exclusive worldwide license from the center to PT-401, an erythropoietin (EPO) dimer to treat anemia. DNAP plans to couple PT-401 with a genetic test for predicting response and individualizing dosage. DNAPrint genomics...
BC Week In Review | Oct 4, 2004
Company News

Biofrontera Pharmaceuticals Holding AG, DNAPrint deal

DNAP will invest E20 million ($24.5 million) over the next two years for a 51.4% stake in Biofrontera in the form of series B shares. The companies also entered a JV to integrate Biofrontera's drug...
BioCentury | Oct 4, 2004
Finance

The brave Atlantic alliance

While European investors continue to put their money into the U.S., a change in the Paris Stock Exchange rules is making it easier for U.S. investors to hunt for bargains in Europe. NicOx (NM:Nicox) last...
BC Week In Review | Aug 18, 2003
Company News

DNAPrint board of directors update

DNAPrint genomics Inc. (DNAP), Sarasota, Fla.   Business: Genomics   Hired: Hector Gomez as chief medical officer  ...
Items per page:
1 - 10 of 30
BC Week In Review | Feb 11, 2008
Company News

DNAPrint, Nanobac deal

The companies signed a letter of intent for Nanobac to acquire pharmacogenetics and consumer genetic test services company DNAPrint for 75 million shares valued at $3 million based on Nanobac's close of $0.04 on Jan....
BioCentury | Dec 10, 2007
Strategy

deCode gets personal

deCode genetics Inc. thinks its new deCODEme personal genotyping service will let it earn a bit of easy cash with very little effort. The company is planning to leverage its understanding of genomics into a...
BC Week In Review | Dec 18, 2006
Clinical News

DNAPrint preclinical data

In a mouse model of anemia, PT-401 was 3 times more effective than conventional erythropoietin (EPO) treatments. PT-401 is dimerized and genetically modified form of EPO. Data were presented at the American Society of Hematology...
BC Week In Review | Aug 28, 2006
Company News

DNAPrint, NeoCodex Inc. deal

DNAG will use its Admixture Mapping technology to identify markers in DNA samples provided by NeoCodex that predict drug response to chemotherapy regimens. DNAPrint Genomics Inc. (DNAG), Sarasota, Fla.   NeoCodex Inc. , Sevilla, Spain  ...
BC Week In Review | Jul 18, 2005
Company News

Biofrontera Pharmaceuticals Holding AG, DNAPrint deal

DNAG acquired an 18% stake in Biofrontera for E1.5 million ($1.8 million). Under the companies' 2004 deal, DNAG can acquire up to 51.4% of Biofrontera (see BioCentury, Oct. 4, 2004). The companies have a JV...
BC Week In Review | Jun 20, 2005
Company News

DNAPrint, Proteos Inc. deal

Proteos, a CRO, will manufacture preclinical batches of DNAP's PT-401 erythropoietin (EPO) dimer to treat anemia. In April, DNAP acquired an exclusive worldwide license to the compound from Beth Israel Deaconess Medical Center (Boston, Mass.)...
BC Week In Review | Apr 11, 2005
Company News

DNAPrint, Beth Israel Deaconess Medical Center deal

DNAP acquired an exclusive worldwide license from the center to PT-401, an erythropoietin (EPO) dimer to treat anemia. DNAP plans to couple PT-401 with a genetic test for predicting response and individualizing dosage. DNAPrint genomics...
BC Week In Review | Oct 4, 2004
Company News

Biofrontera Pharmaceuticals Holding AG, DNAPrint deal

DNAP will invest E20 million ($24.5 million) over the next two years for a 51.4% stake in Biofrontera in the form of series B shares. The companies also entered a JV to integrate Biofrontera's drug...
BioCentury | Oct 4, 2004
Finance

The brave Atlantic alliance

While European investors continue to put their money into the U.S., a change in the Paris Stock Exchange rules is making it easier for U.S. investors to hunt for bargains in Europe. NicOx (NM:Nicox) last...
BC Week In Review | Aug 18, 2003
Company News

DNAPrint board of directors update

DNAPrint genomics Inc. (DNAP), Sarasota, Fla.   Business: Genomics   Hired: Hector Gomez as chief medical officer  ...
Items per page:
1 - 10 of 30